Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners
  • Linkedbio Partnering:

    Lingmed analyst team evaluates the innovative biotech products, technologies and medical devices to estimate the market size, risk & opportunities, to identify the right partner for the asset. Lingmed team will arrange partnering meetings to facilitate the direct dialogues, suggest deal structure to support deal closing

  • Linkedbio Analysis:

    Lingmed analyst team conducts desk researches and interviews to get insights on China market, we provide tailored product China market sizing analysis, deal valuation and competitive landscape reports to our clients

Latest Lingmed asset recommendation
首创瘢痕治疗项目寻求全球合作LMP1835 (Monday, 04 Dec 2023)
  • 全球&中国瘢痕流行病学
  • 中国增生性瘢痕&瘢痕疙瘩的治疗
  • 本期灵麦项目推荐——增生性瘢痕&瘢痕疙瘩项目
Related asset recommendations
美国创新 - 缓释口服治疗2型糖尿病项目寻求全球合作 - LMP1992 LMP1993
欧洲吸入式偏头痛项目寻求中国合作- LMP1987
Latest Lingmed monthly webinar
Research progress in the pathogenesis and treatment of depression, are you ready? (Wednesday, 29 Nov 2023)
Event details
  • Epidemiology and pathogenesis of depression
  • Research progress of anti-depression drugs with different mechanisms of action
  • Top 10 anti-depression drugs in the worldwide & China
  • Global & Chinese Leading companies in CNS therapeutic area
  • An innovative biotech roadshow
Related monthly webinars
Breakthrough & Progress of Non-small cell lung cancer drug , are you ready?
Development progress of new drug development for skin diseases, are you ready?
General information
Product > 412
Company > 801
Deals > 206
Reports > 137
Non-confi PDF > 174